By Peter A. McCullough, MD, MPH
As we look back on the COVID-19 pandemic response debacle, a black spot is the lack of innovation or improved hospital care over time.
Aghasadeghi et al published a small randomized trial of oral supplementation with spirulina.
“Spirulina (arthrospira platensis), a filamentous, gram-negative cyanobacterium, is a blue-green microalga that is a non-nitrogen-fixing photoautotroph (19). Spirulina platensis is rich in protein (over 70%), vitamins, and minerals such as vitamin D, B12, provitamin A (beta carotene), and iron. It also contains phenolic acids, tocopherols, g-linolenic acid, and is particularly high in phycocyanobilin (PCB). PCB, a blue pigment protein, is part of the light-harvesting phycobiliprotein family and has anti-inflammatory, anti-cancer, and antioxidant properties. Spirulina platensis, which does not contain cellulose, is easily digestible (20–22). Previous studies have confirmed the anti-inflammatory properties of Spirulina platensis, demonstrating its ability to prevent and reduce inflammation by inhibiting histamine release from mast cells (20, 23, 24).”
To summarize, spirulina is a blue-green algae product. According to the National Institutes of Health (NIH), people have used doses of up to 19 g per day for a maximum of 2 months and up to 10 g per day for a maximum of 6 months. People should not exceed the dose stated on the product label—most products list a serving as 1 gram. Aghasadeghi described favorable directional changes in inflammatory markers and reductions in hard clinical outcomes with 15.2 g/day of spirulina supplementation in hospitalized COVID-19 patients.
Click this link for the original source of this article.
Author: Peter A. McCullough, MD, MPH
This content is courtesy of, and owned and copyrighted by, https://petermcculloughmd.substack.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.